Category IV indications for therapeutic apheresis—ASFA fourth special issue
Journal of Clinical Apheresis2007Vol. 22(3), pp. 176–180
Citations Over TimeTop 10% of 2007 papers
Beth H. Shaz, Michael Linenberger, Nicholas Bandarenko, Jeffrey L. Winters, Haewon C. Kim, Marisa B. Marques, Ravi Sarode, Joseph E. Schwartz, Robert S. Weinstein, Ashka Wirk, Zbigniew M. Szczepiorkowski
Abstract
The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.
Related Papers
- → Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient(2016)43 cited
- → Therapeutic plasma exchange – A brief review of indications, urgency, schedule, and technical aspects(2019)42 cited
- → Therapeutic apheresis in pediatrics: Technique adjustments, indications and nonindications, a plasma exchange focus(2012)37 cited
- → Apheresis activity in Venezuela(2005)15 cited
- → Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy(2019)11 cited